Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression

Bibliography

• Whiteside TL. Immune responses to malignancies. J Allergy Clin Immunol 2010;125:S272-83
   PubMed Web of Science ®Google Scholar
• Sahin U, Tureci O, Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol 1997;10:709-16
   Google Scholar
• Lee PP, Yee C, Savage PA, Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999;5:677-85
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Immune effector cells in the tumor microenvironment: their role in regulation of tumor progression. In:Yefenof E, editor. Innate and adaptive immunity responses in the tumor microenvironment. Springer Science, Dordrecht, The Netherlands;2008. p.1-34
   Google Scholar
• Klebanoff CA, Gattinoni L, Torabi-Parizi P, Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 2005;102:9571-76
   PubMed Web of Science ®Google Scholar
• Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008;27:5904-12
   PubMed Web of Science ®Google Scholar
• Frey AB, Monu N. Signaling defects in anti-tumor T cells. Immunol Rev 2008;222:192-205
   PubMed Web of Science ®Google Scholar
• Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25:267-96
   PubMed Web of Science ®Google Scholar
• Faries MB, Hsueh EC, Ye X, Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res 2009;15:7029-35
   PubMed Web of Science ®Google Scholar
• Bogunovic D, O'Neill DW, Belitskaya-Levy I, Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA 2009;106:20429-34
   PubMed Web of Science ®Google Scholar
• Sadun RE, Sachsman SM, Chen X, Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy. Clin Cancer Res 2007;13:4016-25
   PubMed Web of Science ®Google Scholar
• Tsuda H. Gene and chromosomal alterations in sporadic breast cancer: correlation with histopathological features and implications for genesis and progression. Breast Cancer 2009;16:186-201
   PubMed Web of Science ®Google Scholar
• Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006;6:836-48
   PubMed Web of Science ®Google Scholar
• Khong HT, Wang QJ, Rosenberg SA. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother 2004;27:184-90
   PubMed Web of Science ®Google Scholar
• Campoli M, Chang CC, Ferrone S. HLA class I antigen loss, tumor immune escape and immune selection. Vaccine 2002;4:A40-5
   Google Scholar
• Aptsiauri NT, Cabrera R, Mendez A, Role of altered expression of HLA class I molecules in cancer progression. Adv Exp Med Biol 2007;601:123-31
   PubMed Web of Science ®Google Scholar
• Whiteside TL, Stanson J, Shurin MR, Ferrone S. Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells. J Immunol 2004;173:1526-34
   PubMed Web of Science ®Google Scholar
• Ferrone S, Whiteside TL. Tumor microenvironment and immune escape. Surg Oncol Clin N Am 2007;16:755-74
   PubMed Web of Science ®Google Scholar
• Houghton AN, Guevara-Patino JA. Immune recognition of self in immunity against cancer. J Clin Invest 2004;114:468-71
   PubMed Web of Science ®Google Scholar
• Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res 2006;12:3890-95
   PubMed Web of Science ®Google Scholar
• Lang S, Atarashi Y, Nishioka Y, B7.1 on human carcinomas: costimulation of T cells and enhanced tumor-induced T-cell death. Cell Immunol 2000;201:132-43
   PubMed Web of Science ®Google Scholar
• Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002;3:611-8
   PubMed Web of Science ®Google Scholar
• Slavik JM, Hutchcroft JE, Bierer BE. CD28/CTLA-4 and CD80/CD86 families: signaling and function. Immunol Res 1999;19:1-24
   PubMed Web of Science ®Google Scholar
• Wieckowski EU, Visus C, Szajnik M, Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol 2009;183:3720-30
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9
   PubMed Web of Science ®Google Scholar
• Strauss L, Bergmann C, Szczepanski M, A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 2007;13:4345-54
   PubMed Web of Science ®Google Scholar
• Mandapathil M, Hilldorfer B, Szczepanski MJ, Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells(TREG). J Biol Chem 2009;285:717-86
   Google Scholar
• Strauss L, Bergmann C, Whiteside TL. Human circulating CD4+CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J Immunol 2009;182:1469-80
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Schrum AG, Cho HI, Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol 2010;184:3106-16
   PubMed Web of Science ®Google Scholar
• Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets 2007;7:31-40
   PubMed Web of Science ®Google Scholar
• Sheng H, Shao J, Morrow JD, Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998;58:362-6
   PubMed Web of Science ®Google Scholar
• Zhou BB, Zhang H, Damelin M, Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009;8:806-23
   PubMed Web of Science ®Google Scholar
• Baniyash M. Chronic inflammation, immunosuppression and cancer: new insights and outlook. Semin Cancer Biol 2006;16:80-8
   PubMed Web of Science ®Google Scholar
• Pikarsky E, Porat RM, Stein I, NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431:461-6
   PubMed Web of Science ®Google Scholar
• de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24-37
   PubMed Web of Science ®Google Scholar
• Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008;222:357-68
   PubMed Web of Science ®Google Scholar
• Winter MC, Hancock BW. Ten years of rituximab in NHL. Expert Opin Drug Saf 2009;8:223-35
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpressed HER2. N Engl J Med 2001;344:783-92
   PubMed Web of Science ®Google Scholar
• Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-57
   PubMed Web of Science ®Google Scholar
• Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med 2002;195:1653-9
   PubMed Web of Science ®Google Scholar
• Engelhardt JJ, Sullivan TJ, Allison JP. CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. J Immunol 2006;177:1052-61
   PubMed Web of Science ®Google Scholar
• Sarnaik AA, Weber JS. Recent advances using anti-CTLA-4 for the treatment of melanoma. Cancer 2009;15:169-73
   Web of Science ®Google Scholar
• Riley JL. PD-1 signaling in primary T cells. Immunol Rev 2009;229:114-25
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99:1229-97
   PubMedGoogle Scholar
• Wang W, Lau R, Yu D, PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25Hi regulatory T cells. Int Immunol 2009;21:1065-77
   PubMed Web of Science ®Google Scholar
• Li MO, Flavell RA. TGF-beta: a master of all T cell trades. Cell 2008;134:392-04
   PubMed Web of Science ®Google Scholar
• Shevach EM, Davidson TS, Huter EN, Role of TGF-beta in the induction of Foxp3 expression and T regulatory cell function. J Clin Immunol 2008;28:640-6
   PubMed Web of Science ®Google Scholar
• Terabe M, Ambrosino E, Takaku S, Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody. Clin Cancer Res 2009;15:6560-9
   PubMed Web of Science ®Google Scholar
• Vicari AP, Trinchieri G. Interleukin-10 in viral diseases and cancer: exiting the labyrinth? Immunol Rev 2004;202:223-36
   PubMed Web of Science ®Google Scholar
• Shurin MR, Yurkovetsky ZR, Tourkova IL, Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10. Int J Cancer 2002;101:61-8
   PubMed Web of Science ®Google Scholar
• Llorente L, Richaud-Patin Y, Garcia-Padilla C, Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000;43:1790-800
   PubMed Web of Science ®Google Scholar
• Khalil M, Vonderheide RH. Anti-CD40 agonist antibodies: preclinical and clinical experience. Update Cancer Ther 2007;2:61-5
   PubMedGoogle Scholar
• Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res 2007;13:108-88
   Google Scholar
• Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann NY Acad Sci 2009;1174:99-06
   PubMed Web of Science ®Google Scholar
• Mahnke K, Schonfeld K, Fondel S, Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 2007;120:2723-33
   PubMed Web of Science ®Google Scholar
• Kaminetzky D, Hymes KB. Denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Biologics 2008;2:717-24
   PubMedGoogle Scholar
• Dannull J, Su Z, Rizzieri D, Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623-33
   PubMed Web of Science ®Google Scholar
• Waldmann TA. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol 2007;27:1-18
   PubMed Web of Science ®Google Scholar
• Liu DV, Maier LM, Hafler DA, Wittrup KD. Engineered interleukin-2 antagonists for the inhibition of regulatory T cells. J Immunother 2009;32:887-94
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Menard C, Puig PE, Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641-8
   PubMed Web of Science ®Google Scholar
• Biswas S, Eisen T. Immunotherapeutic strategies in kidney cancer-when TKIs are not enough. Nat Rev Clin Oncol 2009;6:478-87
   PubMed Web of Science ®Google Scholar
• Finke JH., Rini B, Ireland J, Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14:6674-82
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Finkelstein SE, Surman DR, IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA 2004;101:1969-74
   PubMed Web of Science ®Google Scholar
• Teague RM, Sather BD, Sacks JA, Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med 2006;12:335-41
   PubMed Web of Science ®Google Scholar
• Yu A, Zhu L, Altman NH, Malek TR. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 2009;30:204-17
   PubMed Web of Science ®Google Scholar
• Caserta S, Alessi P, Basso V, Mondino A. IL-7 is superior to IL-2 for ex vivo expansion of tumour-specific CD4+ T cells. Eur J Immunol 2010;40:470-9
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Sportes C, Ahmadzadeh M, IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 2006;29:313-9
   PubMed Web of Science ®Google Scholar
• Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002;13:155-68
   PubMed Web of Science ®Google Scholar
• Cocco C, Pistoia V, Airoldi I. New perspectives for melanoma immunotherapy: role of IL-12. Curr Mol Med 2009;9:459-69
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Kirkwood JM. Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med 2008;6:62
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Tarhini AA, Panelli MC, Next generation of immunotherapy for melanoma. J Clin Oncol 2008;26:3445-55
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158-67
   PubMed Web of Science ®Google Scholar
• Zhou X, Jun DY, Thomas AM, Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine. Cancer Res 2005;65:1079-88
   PubMed Web of Science ®Google Scholar
• Eggermont AM. Immunostimulation versus immunosuppression after multiple vaccinations: the woes of therapeutic vaccine development. Clin Cancer Res 2009;15:6745-7
   Google Scholar
• Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009;9:361-71
   PubMed Web of Science ®Google Scholar
• Charles KA, Kulbe H, Soper R, The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 2009;119:3011-23
   PubMed Web of Science ®Google Scholar
• Baldwin HM, Ito-Ihara T, Isaacs JD, Hilkens CM. Tumor necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis. Ann Rheum Dis 2009. [Epub ahead of print]
   PubMedGoogle Scholar
• Brown ER, Charles KA, Hoare SA, A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol 2008;19:1340-6
   PubMed Web of Science ®Google Scholar
• Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007;7:179-90
   PubMed Web of Science ®Google Scholar
• Mata-Haro V, Cekic C, Martin M, The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007;316:1628-32
   PubMed Web of Science ®Google Scholar
• Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007;117:1184-94
   PubMed Web of Science ®Google Scholar
• Baldridge JR, McGowan P, Evans JT, Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 2004;4:1129-38
   PubMed Web of Science ®Google Scholar
• Smits EL, Cools N, Lion E, The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells. Cancer Immunol Immunother 2010;59:35-46
   PubMed Web of Science ®Google Scholar
• Szczepanski MJ, Czystowska M, Szajnik M, Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 2009;69:3105-13
   PubMedGoogle Scholar
• Davis ID, Chen Q, Morris L, Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. J Immunother 2006;29:499-511
   PubMed Web of Science ®Google Scholar
• Dieli F, Vermijlen D, Fulfaro F, Targeting human gammaδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007;67:7450-7
   PubMed Web of Science ®Google Scholar
• Sarkar FH, Adsule S, Li Y, Padhye S. Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. Mini Rev Med Chem 2007;7:599-608
   PubMed Web of Science ®Google Scholar
• Harris SG, Padilla J, Koumas L, Prostaglandins as modulators of immunity. Trends Immunol 2002;23:144-50
   PubMed Web of Science ®Google Scholar
• Stolina M, Sharma S, Lin Y, Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000;164:361-70
   PubMed Web of Science ®Google Scholar
• Sharma S, Yang SC, Zhu L, Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res 2005;65:5211-20
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007;117:1147-54
   PubMed Web of Science ®Google Scholar
• Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, andmyeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007;13:721s-6s
   PubMed Web of Science ®Google Scholar
• Kumar V, Sharma A. Adenosine: an endogenous modulator of innate immune system with therapeutic potential. Eur J Pharmacol 2009;616:7-15
   PubMed Web of Science ®Google Scholar
• Blackburn MR, Vance CO, Morschl E, Wilson CN. Adenosine receptors and inflammation. Handb Exp Pharmacol 2009;193:215-69
   PubMedGoogle Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15
   PubMed Web of Science ®Google Scholar
• Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004;305:200-05
   PubMed Web of Science ®Google Scholar
• June CH. Principles of adoptive T cell cancer therapy. J Clin Invest 2007;117:1204-12
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Finkelstein SE, Klebanoff CA, Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005;202:907-12
   PubMed Web of Science ®Google Scholar
• Romo de Vivar Chavez A, de Vera ME, Liang X, Lotze MT. The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma. Med Oncol 2009;26(Suppl 1):3-12
   PubMedGoogle Scholar
• Morgan RA, Dudley ME, Wunderlich JR, Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-29
   PubMed Web of Science ®Google Scholar
• Offringa R. Antigen choice in adoptive T-cell therapy of cancer. Curr Opin Immunol 2009;21:190-9
   PubMed Web of Science ®Google Scholar
• Visus CD, Ito DA, Amoscato A, Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. Cancer Res 2007;67:10538-45
   PubMed Web of Science ®Google Scholar
• Morse MA, Hall JR, Plate JM. Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer. Expert Opin Biol Ther 2009;9:331-9
   PubMed Web of Science ®Google Scholar
• Pandolfi F, Cianci R, Lolli S, Strategies to overcome obstacles to successful immunotherapy of melanoma. Int J Immunopathol Pharmacol 2008;21:493-500
   PubMed Web of Science ®Google Scholar
• Morse MA, Hobeika AC, Osada T, Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008;112:610-18
   PubMed Web of Science ®Google Scholar
• Lens M. The role of vaccine therapy in the treatment of melanoma. Expert Opin Biol Ther 2008;8:315-23
   PubMed Web of Science ®Google Scholar
• Engell-Noerregaard L, Hansen TH, Andersen MH, Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009;58:1-14
   PubMed Web of Science ®Google Scholar
• Lacelle MG, Jensen SM, Fox BA. Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy. Clin Cancer Res 2009;15:6881-90
   Google Scholar
• Stolz C, Schuler M. Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention. Leuk Lymphoma 2009;50:873-85
   PubMed Web of Science ®Google Scholar
• Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007;18:977-84
   PubMed Web of Science ®Google Scholar
• Martinelli E, De Palma R, Orditura M, Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 2009;158:1-9
   PubMed Web of Science ®Google Scholar
• Hsu JY, Wakelee HA. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs 2009;23:289-304
   PubMed Web of Science ®Google Scholar
• Houot R, Goldstein MJ, Kohrt HE, Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood 2009;114:3431-8
   PubMed Web of Science ®Google Scholar
• Wu JJ, Huang DB, Tyring SK. 2004. Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. Antiviral Res 2004;64:79-83
   PubMed Web of Science ®Google Scholar
• Fridman JS, Caulder E, Hansbury M, Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin Cancer Res 2007;13:1892-902
   PubMed Web of Science ®Google Scholar
• Kreitman RJ. Immunotoxins for targeted cancer therapy. AAPS J 2006;8:E532-51
   PubMed Web of Science ®Google Scholar
• Serafini P, Meckel K, Kelso M, Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006;203:2691-702
   PubMed Web of Science ®Google Scholar